Actemra 162 MG/0.9 ML syringe 0.9ML
Ended Awarded Last action
- Contract number
- SPE2DR26FT4MY
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,617
Award facts
- Contract value 100% obligated
- $3,616.62 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,616.62 to AmerisourceBergen Drug Corp for Actemra 162 mg/0.9 mL syringes on December 8, 2025, with an ultimate completion date of December 9, 2025. This firm fixed-price delivery order represents a non-competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle running through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract under this larger IDC, this delivery order enables the Defense Health Agency and other federal healthcare systems to procure critical pharmaceutical products through a flexible contracting mechanism designed to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has demonstrated extensive capability in fulfilling federal medical procurement requirements through competitive and non-competitive awards with the DLA. The company's contract portfolio spans a comprehensive range of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. This delivery order for Actemra, a biologic immunosuppressant used in treating rheumatoid arthritis and other inflammatory conditions, reflects the company's critical role in supplying specialized medications to support military healthcare needs.
Quick answers
Who was awarded contract SPE2DR26FT4MY?
SPE2DR26FT4MY was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FT4MY worth?
The government has obligated $3,617 on SPE2DR26FT4MY.
Is contract SPE2DR26FT4MY an order under another contract?
Yes. SPE2DR26FT4MY is a delivery order under SPE2DR25D3201, an indefinite delivery contract.
Was contract SPE2DR26FT4MY competed?
The extent of competition for SPE2DR26FT4MY was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award